This review highlights nanotechnology-based drug delivery systems, such as nanoparticles and liposomes, for ocular diseases.
Annals of Medicine and Surgery · 7 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This review highlights nanotechnology-based drug delivery systems, such as nanoparticles and liposomes, for ocular diseases.
This review article synthesizes literature on nanotechnology-based drug delivery systems for ocular diseases, focusing on anterior segment conditions. Methods include evaluating various nanocarriers like liposomes, nanoparticles, and nanoemulsions for their formulation, characterization, and preclinical testing. Central results indicate that nanocarriers can offer advantages over conventional therapies, such as increased drug bioavailability, sustained release, and targeted delivery. Limitations noted include a general lack of comprehensive safety and toxicity data for many systems and the need for further research on stability and biocompatibility.